Lilly shares safety, tolerability data on its next-generation obesity drugstatnews.com
Lilly’s triple agonist, retreutide, significantly improved weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential in the treatment of obesity and its complications.investors.lilly.com
Eli Lilly says next-generation obesity drug curbs sleep apnea, among other benefitsreuters
A new wave of weight loss therapies aim to be better than today’s GLP-1smarket Watch
ADA: Lilly unveils impressive triple-G efficacy in patients with obesity, diabetesfierce biotech
